Learn about our mission, research interests and goals, and organization.
Center for Immuno-Oncology
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
View a listing of our most recent publications.
The CCR’s Center for Immuno-oncology (CIO) explores fundamental questions of cancer immunotherapy through rigorous preclinical studies and translates these findings into clinical trials with the goal of developing novel therapies for a spectrum of cancers.
CCR’s long history of excellence in immunology has contributed to advances in immunotherapies now widely used to treat many patients who have cancer. The CIO acts as a hub for CCR’s many immuno-oncology efforts to further promote and support these efforts and build on the existing expertise, serving as a nexus for multidisciplinary and collaborative efforts among investigators in multiple laboratories, branches and programs across CCR, NCI, and NIH, as well as with investigators in the academic community and the private sector.
About Our Center
PI & Key Staff
NCI Immunotherapy Fellowship Overview
This training program is designed for physicians who have completed a medical oncology fellowship program in the United States and who seek specialized training in immunotherapy with clinical trials and clinical trial development.
There are multiple opportunities for training in clinical immunotherapy at the Center for Cancer Research (CCR), National Cancer Institute (NCI), with active clinical programs in therapeutic cancer vaccines, immune checkpoint modulation, adoptive cellular therapies (both TCR transgenic and CAR-T therapy) and antibody-based immunotherapies. This training program, at the CCR in Bethesda, Maryland, allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy. This 1-year fellowship provides opportunities to understand how to design, write and run clinical trials, how to treat patients, how manage toxicities, as well as opportunities to work with multiple experimental agents.
Surgery Branch / Cancer Immunotherapy Research Fellowship
This training program is for general surgery residents who have completed at least two years of an ACGME accredited general surgery residency. The program provides training in Surgical Oncology, an immersive experience in immunotherapy laboratory research, and clinical human research in early phase trials.
Multimodal immunotherapy to Engage, Expand, Enable, and Evolve anti-tumor immune responses.
Fabian, et al. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J Immunother Cancer. 2021;9(2):e001691.